Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Methods of designing two-stage winner trials with survival outcomes.

Fang F, Lin Y, Shih WJ, Li Y, Yang J, Zhang X.

Stat Med. 2014 Apr 30;33(9):1539-63. doi: 10.1002/sim.6070.

2.
3.

An alternative phase II/III design for continuous endpoints.

Huang WS, Liu JP, Hsiao CF.

Pharm Stat. 2011 Mar-Apr;10(2):105-14. doi: 10.1002/pst.418.

PMID:
20186724
4.
5.

Time-to-event analysis with treatment arm selection at interim.

Di Scala L, Glimm E.

Stat Med. 2011 Nov 20;30(26):3067-81. doi: 10.1002/sim.4342. Erratum in: Stat Med. 2013 May 20;32(11):1974.

PMID:
21898523
6.

Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.

Bretz F, Schmidli H, König F, Racine A, Maurer W.

Biom J. 2006 Aug;48(4):623-34.

PMID:
16972714
7.

Confirmatory clinical trials with an adaptive design.

Koch A.

Biom J. 2006 Aug;48(4):574-85.

PMID:
16972708
8.

Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.

Kimani PK, Glimm E, Maurer W, Hutton JL, Stallard N.

Stat Med. 2012 Aug 30;31(19):2068-85. doi: 10.1002/sim.5326.

PMID:
22437262
9.

Optimizing the data combination rule for seamless phase II/III clinical trials.

Hampson LV, Jennison C.

Stat Med. 2015 Jan 15;34(1):39-58. doi: 10.1002/sim.6316.

10.

Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.

Kimani PK, Todd S, Stallard N.

Stat Med. 2013 Jul 30;32(17):2893-910. doi: 10.1002/sim.5757.

11.

Dose selection in seamless phase II/III clinical trials based on efficacy and safety.

Kimani PK, Stallard N, Hutton JL.

Stat Med. 2009 Mar 15;28(6):917-36. doi: 10.1002/sim.3522.

PMID:
19152231
12.

Seamless Phase II/III combination study through response adaptive randomization.

Wang L, Cui L.

J Biopharm Stat. 2007;17(6):1177-87.

PMID:
18027224
13.

Group-sequential methods for adaptive seamless phase II/III clinical trials.

Stallard N.

J Biopharm Stat. 2011 Jul;21(4):787-801. doi: 10.1080/10543406.2011.551335. Review.

PMID:
21516569
14.
15.

An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.

Taylor DJ, Grobler A, Abdool Karim SS.

Clin Trials. 2012 Aug;9(4):377-84. doi: 10.1177/1740774512445512.

PMID:
22610168
16.

Designing a series of decision-theoretic phase II trials in a small population.

Hee SW, Stallard N.

Stat Med. 2012 Dec 30;31(30):4337-51. doi: 10.1002/sim.5573.

PMID:
22927289
18.

Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.

Stallard N, Kunz CU, Todd S, Parsons N, Friede T.

Stat Med. 2015 Oct 15;34(23):3104-15. doi: 10.1002/sim.6567.

19.

A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints.

Kunz CU, Friede T, Parsons N, Todd S, Stallard N.

J Biopharm Stat. 2015;25(1):170-89. doi: 10.1080/10543406.2013.840646.

20.

Acute ischemic stroke trials.

Saver JL, Kidwell CS, Liebeskind DS, Starkman S.

Stroke. 2001 Jan;32(1):275-8. No abstract available.

PMID:
11136948

Supplemental Content

Support Center